Report: Pharmaceutical R&D Projects to Discover Cures for Patients with Neglected Conditions
IFPMA
January 2013
Announcement text
The IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) released its 2012 status report on pharmaceutical R&D to address neglected diseases that disproportionately affect people in low- and middle-income countries. Representing a 40 percent increase over 2011, the 132 R&D projects in the 2012 update focus on the following diseases prioritized by the World Health Organization’s Special Programme for Research and Training in Tropical Diseases (TDR): tuberculosis, malaria, human African trypanosomiasis (sleeping sickness), leishmaniasis, dengue, onchocerciasis (River blindness), American trypanosomiasis (Chagas disease), schistosomiasis, leprosy and lymphatic filariasis.
The only major sector increasing R&D funding for neglected diseases in 2011, the research-based pharmaceutical industry has a long-standing and continuing commitment to fighting these conditions. Industry’s holistic approach includes R&D projects, capacity-strengthening efforts, and medicine donations.
“We take a comprehensive approach to tacking neglected diseases,” says Eduardo Pisani, IFPMA Director General, “Donations of 14 billion treatments this decade address patients’ near-term needs while these 132 R&D programs will bring innovative vaccines and treatments to meet future needs and hopefully stop these dreaded diseases.”
http://www.ifpma.org/fileadmin/content/News/2013/IFPMA_News_Release_RD_Status_Report_16Jan2013.pdf
vaccines and global health :: ethics and policy 